An interventional study of Ozurdex implant in Retinal Vein Occlusion (RVO) and Macular Edema, sponsored by Retina Research Institute, LLC. Terminated at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-02.
Sponsored by Retina Research Institute, LLC · Not applicable, Interventional, and Treatment
To determine if Ozurdex implant can offer an effective treatment for macular edema associated with retinal vein occlusion when treatment with intravitreal Avastin, Lucentis, or Eylea have not demonstrated a significant response.
To determine whether Ozurdex implant can offer an efficacious alternative for treatment of macular edema in the setting of retinal vein occlusion when treatment with intravitreal bevacizumab (Avastin),ranibizumab (Lucentis), and/or aflibercept (Eylea) have not demonstrated significant response.
841 studies on the registry are indexed under Macular Edema; 56 are open to participants now.
This study's enrollment of 10 is below the median of 50 across 619 interventional studies indexed under Macular Edema.
Browse Macular Edema studies →Retina Research Institute, LLC is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients with Retinal Vein Occlusion (RVO) with available initial imaging and documented treatment failure with bevacizumab, ranibizumab, or aflibercept. Treatment failure is defined as lack of anatomic improvement (persistent intraretinal cystic changes/macular edema with central subfield thickness greater than 250 microns on time-domain OCT or greater than 275 microns on spectral domain OCT) with lack of visual improvement (less than 2 lines of visual gain by Snellen acuity), despite 3 to 6 intravitreal anti-VEGF treatments over the preceding 6 months.
Exclusion Criteria:
Intravitreal injection of Ozurdex implant
Drug: Ozurdex implant
Intravitreal injection of Dexamethasone implant
Also known as: Dexamethasone implant
Improvement in best-corrected Snellen visual acuity following initiation of Ozurdex therapy
Time frame: 6 Months
Anatomic/angiographic improvement in macular edema as evaluated by OCT and fluorescein angiography
Time frame: 6 Months
This study is terminated, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Retina Research Institute, LLC